N/A N=40 Open Label Study Using OsteoProbe System
Adverse Effects in the Use of the OsteoProbe System
Primary: The Number of Participants With Reported Device Related Serious Adverse Events. — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=23 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral
Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001
N/A N=34 EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy
Bone Metastases · Fractures, Bone · Bone Tumor
Primary: Successful Introducer Insertion With the EPIONE Device. — 89 Successful insertion
N/A N=20 Mini Stem DEXA (Dual Energy X-ray Absorptiometry)
Osteoarthritis, Hip
Primary: DEXA Analysis of BMD at Preoperative Visit — 0.8; 1.0; 1.6; 2.0 g/cm^2
N/A N=50 Powered Bone Marrow Aspiration and Core Biopsy System Compared to Manual Devices
Bone Marrow Biopsy Procedures
Primary: Subject Reported Level of Pain During Procedure — 3.8; 3.2 units on a scale
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
N/A N=100 Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy
Plasma Cell Myeloma
Primary: Bone Marrow Core Biopsy Length (in mm) and Artifacts Assessed by the Pathologist — 14; 9.5 Millimeters
Phase 3 N=200 Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy
Osteoporosis
Primary: Summary of Forteo B Pen Complaints at 8 Weeks — 47; 4; 27; 8 number of complaints
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
N/A N=48 Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis
Postmenopausal Osteoporosis · Osteopenia · Jaw, Edentulous, Partially
Primary: Marginal Bone Level Alterations — -0.15; -0.06 millimeter
Phase 3 N=161 Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
Osteopenia
Primary: Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12 — -1.486; -1.255 Percent Change — p=0.7096
N/A N=25 Evaluation of the Trabecular Metal™ Revision Hip Cup Using Bone Mineral Density (DEXA)
Revision, Joint
Primary: Periprosthetic Bone Mineral Density (BMD) of Hip — 1.63; 1.64; 1.85; 1.64 g/cm^2
N/A N=36 Texture Analysis for Postmenopausal Osteoporosis
Osteoporosis · Osteopenia
Primary: Changes in Lumbar Spine BMD +/- Treatment With Alendronate — 5.28; -1.48 Percent Change
Phase 2 N=57 The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
N/A N=18 Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2
Osteopenia
Primary: Percent Change in Blood-based Biomarker of Bone Loss — 8.8; -5.4 Percent change — p=<0.001
Phase 4 N=69 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…
N/A N=15 Comparing Powered Ported Bone Marrow Aspiration to Manual Standard Bone Marrow Aspiration Procedures
Healthy
Primary: Quality of Aspirate Specimen Yield Total Score -Jamshidi Manual Standard Device — 4.83; 5.75; 1.5; 1.5 units on a scale
Phase 1 N=22 Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
Postmenopausal Osteoporosis
Primary: Abaloparatide Maximum Plasma Concentration (Cmax) on Day 29 — 399.6 picograms/milliliter (pg/mL)
N/A N=206 OsteoCool Tumor Ablation Post-Market Study
Metastasis Spine · Metastasis to Bone
Primary: Change of Worst Pain Score: Thoracic/Lumbar Spine RF Ablation — -4.1 units on a scale — p=<0.0001
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=3,304 Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)
Osteoporosis
Primary: Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs) — 231 Participants
Phase 3 N=511 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 10.8571; 7.1361 percent change
Phase 4 N=69 Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
Osteoporosis, Post-menopausal
Primary: Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months — 5.60; 0.16 percentage of surface — p=<0.001
N/A N=84 Clinical Evaluation of the OrthoPAT Advance System
Transmission, Blood, Recipient/Donor
Primary: Washed RBC Hematocrit — 55.43; 56.48 percentage of HcT
N/A N=579 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets
Osteoporosis
Primary: Cumulative Percentage of Participants With New or Worsening Vertebral Body Fractures — 5.43; 7.35; 7.80; 8.82 Percentage of Participants
Phase 4 N=34 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
Postmenopausal Osteoporosis
Primary: Cancellous Bone Formation Rate at Month 3 — 0.13; 0.01; 0.06 mm3/mm2/day
N/A N=11 Alendronate in Juvenile Osteoporosis
Juvenile Osteoporosis · Low Bone Density · Fractures
Primary: Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). — 11 participants
N/A N=351 Effects of Exemestane on Bone Strength
Osteoporosis · Breast Cancer
Primary: Mean Percent Change in Total Volumetric Bone Mineral Density (BMD) Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-PQCT) From Baseline to 24…
Phase 2 N=50 Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Osteoporosis
Primary: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) — -0.0026; 0.1299; 0.1196; -0.0029 gram per centimeter squared…
Phase 4 N=33 µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Osteoporosis, Osteopenia
Primary: Percentage of Change in Trabecular Surface-to-curve Ratio — 9.1; 7.1 Percentage of Change